WO2002097128A3 - Verfahren zur identifizierung von substanzen gegen herzmuskelzellen-hypertrophie - Google Patents

Verfahren zur identifizierung von substanzen gegen herzmuskelzellen-hypertrophie Download PDF

Info

Publication number
WO2002097128A3
WO2002097128A3 PCT/EP2002/005924 EP0205924W WO02097128A3 WO 2002097128 A3 WO2002097128 A3 WO 2002097128A3 EP 0205924 W EP0205924 W EP 0205924W WO 02097128 A3 WO02097128 A3 WO 02097128A3
Authority
WO
WIPO (PCT)
Prior art keywords
myocardial cell
cell hypertrophy
directed against
identifying substances
against myocardial
Prior art date
Application number
PCT/EP2002/005924
Other languages
English (en)
French (fr)
Other versions
WO2002097128A2 (de
Inventor
Thomas Henkel
Volker Roenicke
Barbara Nave
Original Assignee
Medigene Ag
Thomas Henkel
Volker Roenicke
Barbara Nave
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medigene Ag, Thomas Henkel, Volker Roenicke, Barbara Nave filed Critical Medigene Ag
Publication of WO2002097128A2 publication Critical patent/WO2002097128A2/de
Publication of WO2002097128A3 publication Critical patent/WO2002097128A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Ein Gegenstand der Erfindung ist ein Verfahren zur in vitro Untersuchung von Herzmuskelzellen-Hypertrophie, dadurch gekennzeichnet, daß mindestens ein Parameter für Herzmuskelzellen-Hypertrophie über die Expressionsrate eines heterologen Markerproteins in mindestens einer Herzmuskelzelle enthaltend eine Nukleinsäure kodierend für das heterologe Markerprotein, messbar ist.
PCT/EP2002/005924 2001-05-30 2002-05-29 Verfahren zur identifizierung von substanzen gegen herzmuskelzellen-hypertrophie WO2002097128A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10126371.6 2001-05-30
DE10126371A DE10126371A1 (de) 2001-05-30 2001-05-30 Verfahren zur Identifizierung von Substanzen gegen Herzmuskelzellen-Hypertrophie

Publications (2)

Publication Number Publication Date
WO2002097128A2 WO2002097128A2 (de) 2002-12-05
WO2002097128A3 true WO2002097128A3 (de) 2003-09-12

Family

ID=7686664

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/005924 WO2002097128A2 (de) 2001-05-30 2002-05-29 Verfahren zur identifizierung von substanzen gegen herzmuskelzellen-hypertrophie

Country Status (2)

Country Link
DE (1) DE10126371A1 (de)
WO (1) WO2002097128A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9945840B2 (en) 2004-04-07 2018-04-17 Axiogenesis Ag Non-invasive, in vitro functional tissue assay systems
DE602005025106D1 (de) 2004-05-11 2011-01-13 Axiogenesis Ag Methoden zur medikamentenaufspürung auf der basis von in vitro differenzierten zellen

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999004636A1 (en) * 1997-07-22 1999-02-04 The General Hospital Corporation Evaluation of, delivery of, and use of agents to treat heart disorders
WO1999024571A2 (en) * 1997-11-10 1999-05-20 Curagen Corporation Differentially expressed genes in cardiac hypertrophy and their uses in treatment and diagnosis
WO2000073445A2 (en) * 1999-06-02 2000-12-07 Genentech, Inc. Interleukin-1-receptor associated kinase-3 (irak3)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6201165B1 (en) * 1997-10-16 2001-03-13 Board Of Regents, University Of Texas System Transgenic animal models for cardiac hypertrophy and methods of use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999004636A1 (en) * 1997-07-22 1999-02-04 The General Hospital Corporation Evaluation of, delivery of, and use of agents to treat heart disorders
WO1999024571A2 (en) * 1997-11-10 1999-05-20 Curagen Corporation Differentially expressed genes in cardiac hypertrophy and their uses in treatment and diagnosis
WO2000073445A2 (en) * 1999-06-02 2000-12-07 Genentech, Inc. Interleukin-1-receptor associated kinase-3 (irak3)

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ALLAMANE S ET AL: "p53 status and gene transfer experiments using CMV enhancer/promoter.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 280, no. 1, 12 January 2001 (2001-01-12), pages 45 - 47, XP002220017, ISSN: 0006-291X *
BRUENING W ET AL: "Activation of stress-activated MAP protein kinases up-regulates expression of transgenes driven by the cytomegalovirus immediate/early promoter", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 26, no. 2, 15 January 1998 (1998-01-15), pages 486 - 489, XP002182924, ISSN: 0305-1048 *
KATO T ET AL: "Calmodulin kinases II and IV and calcineurin are involved in leukemia inhibitory factor-induced cardiac hypertrophy in rats.", CIRCULATION RESEARCH. UNITED STATES 10 NOV 2000, vol. 87, no. 10, 10 November 2000 (2000-11-10), pages 937 - 945, XP002220020, ISSN: 1524-4571 *
KOVACS DORA M ET AL: "Discordant estimates of heterologous promoter activity as determined by reporter gene mRNA levels and enzyme activity.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 189, no. 2, 1992, pages 912 - 918, XP002220018, ISSN: 0006-291X *
NABIROCHKINA E ET AL: "Treatment by methyl methanesulfonate induces up-regulation of cytomegalovirus immediate/early promoter", BIOTECHNIQUES, EATON PUBLISHING, NATICK, US, vol. 29, no. 4, October 2000 (2000-10-01), pages 732 - 736, XP002182925, ISSN: 0736-6205 *
TAKEMOTO YASUHIKO ET AL: "Increased JNK, AP-1 and NF-kappaB DNA binding activities in isoproterenol-induced cardiac remodeling.", JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, vol. 31, no. 11, November 1999 (1999-11-01), pages 2017 - 2030, XP002220019, ISSN: 0022-2828 *

Also Published As

Publication number Publication date
WO2002097128A2 (de) 2002-12-05
DE10126371A1 (de) 2003-02-27

Similar Documents

Publication Publication Date Title
AU2001235479A1 (en) Container for nucleic acid analysis
AU2002322518A1 (en) Methods for preparing nucleic acid samples
AU2002304705A1 (en) Method for analysing nucleic acid chains
WO2004092708A3 (en) Methods for the electrochemical detection of target compounds
WO1999064592A3 (en) Green fluorescent proteins for measuring the ph of a biological sample
AU2002367180A1 (en) Concentration measuring method
AU2002314693A1 (en) Nucleic acid amplification method
DE60213803D1 (en) Happier mapping
WO2003046148A3 (en) Polypeptide quantitation
WO2003025154A3 (en) Methods and compositions for the construction and use of fusion libraries
MXPA06000092A (es) Transformacion de cloroplasto de la lenteja de agua.
AU2002217216A1 (en) Method for magnetising chemical or biological markers
AU2002356632A1 (en) Method for determining nucleic acid analytes
WO2002022826A3 (en) Methods and compositions for the construction and use of fusion libraries
WO2002097128A3 (de) Verfahren zur identifizierung von substanzen gegen herzmuskelzellen-hypertrophie
AU2002244757A1 (en) Method for specifically detecting, isolating and characterizing cells from body samples by transfecting nucleic acid constructs
AU2002328803A1 (en) Marker for identifying hematopoietic stem cells
WO2003065012A3 (en) Compositions and methods for reporting of protease activity within the secretory pathway
AU2003303869A1 (en) Methods for nucleic acid analysis
AUPS064202A0 (en) Improved method for the analysis of nucleic acid samples
WO2003031612A3 (en) Method for determining cell cycle position
AU2002328909A1 (en) Nucleic acid molecules encoding proteins essential for plant growth
WO2004013606A3 (en) Species specific dna detection
AU2003285775A1 (en) Method for identifying, analyzing and/or cloning nucleic acid isoforms
WO2002086505A3 (en) Intracellular analysis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP